Provision Language
Background
II. The University has developed a solid drug nanoparticle technology which may help reduce the oral dosage of certain anti-retroviral HIV treatments and therefore may help reduce the cost of such anti-retroviral based HIV treatment regimens. The University would like to maximise the impact of this technology and to reach as many people living with HIV as possible, in the most affordable manner for low- and middle-income countries. The University acknowledges that outside the Territory (namely high income countries) access to drugs in low income groups can also be a challenge and the University’s licensing strategy for HIV drugs and other essential medicines aims to be socially responsible.
[…]
V. The intent of this Agreement is to provide access to Licensed Technology, and not to create any non-intellectual property-related barriers.